Caseware UK (AP4) 2023.0.135 2023.0.135 2024-10-312024-10-312falsefalse2023-11-01Community Pharmacy2truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 08302104 2023-11-01 2024-10-31 08302104 2022-11-01 2023-10-31 08302104 2024-10-31 08302104 2023-10-31 08302104 c:Director1 2023-11-01 2024-10-31 08302104 d:CurrentFinancialInstruments 2024-10-31 08302104 d:CurrentFinancialInstruments 2023-10-31 08302104 d:Non-currentFinancialInstruments 2024-10-31 08302104 d:Non-currentFinancialInstruments 2023-10-31 08302104 c:FRS102 2023-11-01 2024-10-31 08302104 c:AuditExempt-NoAccountantsReport 2023-11-01 2024-10-31 08302104 c:FullAccounts 2023-11-01 2024-10-31 08302104 c:PrivateLimitedCompanyLtd 2023-11-01 2024-10-31 08302104 6 2023-11-01 2024-10-31 08302104 e:PoundSterling 2023-11-01 2024-10-31 iso4217:GBP xbrli:pure

Registered number: 08302104










LIONWOOD PHARMACY LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 OCTOBER 2024

 
LIONWOOD PHARMACY LIMITED
REGISTERED NUMBER: 08302104

STATEMENT OF FINANCIAL POSITION
AS AT 31 OCTOBER 2024

2024
2023
Note
£
£

  

Fixed assets
  

Investments
 4 
387,210
387,210

  
387,210
387,210

Current assets
  

Cash at bank and in hand
 5 
200
200

  
200
200

Creditors: amounts falling due within one year
 6 
(452,432)
(391,335)

Net current liabilities
  
 
 
(452,232)
 
 
(391,135)

Total assets less current liabilities
  
(65,022)
(3,925)

  

Creditors: amounts falling due after more than one year
 7 
(37,500)
(87,500)

  
(102,522)
(91,425)

  

  

Net assets excluding pension asset
  
(102,522)
(91,425)

Net liabilities
  
(102,522)
(91,425)


Capital and reserves
  

Called up share capital 
  
200
200

Profit and loss account
  
(102,722)
(91,625)

  
(102,522)
(91,425)


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

Page 1

 
LIONWOOD PHARMACY LIMITED
REGISTERED NUMBER: 08302104
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 OCTOBER 2024

The Company has opted not to file the income statement in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Mr K V Ondhia
Director

Date: 11 July 2025

The notes on pages 3 to 5 form part of these financial statements.

Page 2

 
LIONWOOD PHARMACY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

1.


General information

Lionwood Pharmacy Limited is a private company, limited by share capital, incorporated in England and Wales under registration number 08302104. The registered office address of the company is Level 5A, Maple House, 149 Tottenham Court Road, London, W1T 7NF.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Going concern

The financial statements have been prepared on the assumption that the company will have the continued financial support of the shareholders. The shareholders of the company have sufficient resources to finance the company as and when the need arises.
The financial statements have been prepared on a going concern basis which is dependent on the financial support of the shareholders to ensure that the company will continue in operational existence for the foreseeable future.

 
2.3

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.4

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

 
2.5

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each reporting date. Gains and losses on remeasurement are recognised in the Income statement for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

 
2.6

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Page 3

 
LIONWOOD PHARMACY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

2.Accounting policies (continued)

 
2.7

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The average monthly number of employees, including directors, during the year was 2 (2023 - 2).


4.


Fixed asset investments





Investments in subsidiary companies

£



Cost or valuation


At 1 November 2023
387,210



At 31 October 2024
387,210





5.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
200
200

200
200


Page 4

 
LIONWOOD PHARMACY LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

6.


Creditors: Amounts falling due within one year

2024
2023
£
£

Bank loans
50,000
50,000

Amounts owed to group undertakings
396,992
335,895

Directors' loan account
4,000
4,000

Accruals
1,440
1,440

452,432
391,335


Secured loans
Bank loans are secured by a fixed and floating charge over the assets of the company.


7.


Creditors: Amounts falling due after more than one year

2024
2023
£
£

Bank loans
37,500
87,500

37,500
87,500


Secured loans
Bank loans are secured by a fixed and floating charge over the assets of the company.


8.


Controlling party

The company was the control of the directors Mr K V Ondhia and Mrs J K Ondhia by virtue of the fact that between them they own 100% of the issued share capital.

 
Page 5